This study evaluated changes in overall survival (OS) among patients diagnosed with AML from 2004 to 2019 using the National Cancer Database. The analysis included 67, 895 patients aged ≥ 18 years, divided into three diagnosis eras: 2004-2010, 2011-2016, and 2017-2019. Median OS steadily improved over time: 7. 6 months in 2004-2010, 8. 6 months in 2011-2016, and 10. 4 months in 2017-2019. The impact of age, AML subtype, chemotherapy, and HCT on OS changed over time, especially showing a stronger positive association with chemotherapy and HCT after 2017. OS remained lower in males, non-Hispanics, racial groups other than Black or White, individuals with a CCI> 0, those with public or no insurance, and those with an annual income <35000. Our findings demonstrate that survival has improved significantly, coinciding with the introduction of venetoclax-based regimens and targeted therapies for FLT3 and IDH1/2 mutations, although disparities by socioeconomic factors persist.
Simkhada et al. (Sat,) studied this question.